All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
December 2023: Hyperhidrosis updates
News
December 2023: Hyperhidrosis updates
Commissioning Policy
The routine commissioning of botulinum toxin A for the management of hyperhidrosis is accepted in Devon for patients with severe axillary hyperhidrosis. Patients must have a Hyperhidrosis Disease Severity Scale (HDSS) score of 3 or 4 (sweating is barely tolerable/intolerable and frequently/always interferes with daily activities) despite at least six weeks of topical aluminium chloride and self-management strategies, AND a resting sweat production of at least 100mg/5 minutes (per axilla).
- Click here for the commissioning policy.
- Click here for the formulary entry.
Revised formulary guidance
The hyperhidrosis guidance has been updated to incorporate the oral treatments, oxybutynin (off-label) and propantheline, for the management of primary and secondary hyperhidrosis.
- Click here for the formulary guidance.
Drug changes
Oxybutynin, immediate-release and modified-release (off-label), and propantheline 15mg tablets have been reclassified from amber (specialist input) to blue (second line) for the treatment of hyperhidrosis.
- Click here for the oxybutynin formulary entry.
- Click here for the propantheline formulary entry.
